Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

NCT04296019 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Colo-rectal Cancer

Interventions

DRUG: Fruquintinib

Sponsor

Shanghai Zhongshan Hospital